HomeAboutRankingsData Sources
© 2026 GeneE
🧬
GeneE
25 sources retrieved · Most recent: April 2026 · Index updated 14 days ago
ⓘGeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
PSMA7
proteasome 20S subunit alpha 7
Chromosome 20 · 20q13.33
NCBI Gene: 5688Ensembl: ENSG00000101182.16HGNC: HGNC:9536UniProt: A0A0K0K1K4
312PubMed Papers
20Diseases
6Drugs
0Pathogenic Variants
FUNCTIONAL ROLE
Hub Gene
CLINICAL
FDA Approved Target
DATA QUALITY
✓ Experimental GO Evidence✓ Swiss-Prot Reviewed
regulation of proteasomal protein catabolic processresponse to oxidative stressproteasomal protein catabolic processproteasome core complex, alpha-subunit complexmultiple myelomaneoplasmMantle cell lymphomaHIV infection
✦AI Summary

PSMA7 (proteasome 20S subunit alpha 7) is a core catalytic component of the 20S proteasome complex that mediates ubiquitin-dependent and -independent protein degradation. As part of the 26S proteasome, PSMA7 participates in ATP-dependent degradation of ubiquitinated proteins essential for maintaining protein homeostasis 1. Beyond canonical proteasomal function, PSMA7 serves specialized roles including modulation of HIF-1α stability, nuclear translocation of androgen receptors, hepatitis C virus translation, and regulation of innate immune responses through MAVS degradation. PSMA7 directly interacts with and mediates proteasome-dependent degradation of NOD1, a pattern recognition receptor involved in innate immunity 2. In disease contexts, PSMA7 shows contrasting roles: pan-cancer analysis reveals frequent 20q13.33 amplification of PSMA7 associated with adverse prognosis across multiple tumor types, where elevated expression promotes cancer growth 3. However, in cutaneous squamous cell carcinoma, higher PSMA7 expression correlates with favorable prognosis and suppresses progression by degrading NOD1 and MAVS, reducing cancer-associated cytokine production 4. PSMA7 elevation in NSCLC promotes metastasis through epithelial-mesenchymal transition, yet melittin-induced PSMA7 degradation suppresses lung cancer metastasis 5. PSMA7 emerged as a plasma biomarker for endometrial cancer detection 6, suggesting clinical diagnostic potential alongside its therapeutic relevance.

Sources cited
1
PSMA7 is an alpha-type subunit of the 20S proteasome core complex participating in ubiquitin-proteasome pathway for protein degradation, regulating cell proliferation, transcription, immune/stress response, and apoptosis
PMID: 19442227
2
PSMA7 directly interacts with NOD1 and downregulates NOD1 expression through proteasome-dependent degradation, inhibiting NOD1-mediated apoptosis and NF-κB activation
PMID: 23839082
3
PSMA7 amplification at 20q13.33 is frequent across multiple cancer types and correlates with adverse prognosis; elevated PSMA7 expression is essential for cancer cell growth
PMID: 38321088
4
In cutaneous squamous cell carcinoma, high PSMA7 expression associates with favorable recurrence-free survival and suppresses progression by degrading NOD1 and MAVS, reducing cancer-associated cytokines
PMID: 37369480
5
PSMA7 elevation promotes NSCLC metastasis and epithelial-mesenchymal transition; melittin suppresses lung cancer metastasis by promoting RNF20-mediated ubiquitination and degradation of PSMA7
PMID: 41254650
6
PSMA7 is a component of a 3-biomarker plasma protein panel that predicts endometrial cancer with AUC of 0.87, sensitivity of 75%, and specificity of 84%
PMID: 38513301
Disease Associationsⓘ20
multiple myelomaOpen Targets
0.60Moderate
neoplasmOpen Targets
0.52Moderate
Mantle cell lymphomaOpen Targets
0.50Moderate
HIV infectionOpen Targets
0.48Moderate
amyloidosisOpen Targets
0.37Weak
cataractOpen Targets
0.30Weak
trauma complicationOpen Targets
0.30Weak
glioblastoma multiformeOpen Targets
0.27Weak
brain glioblastomaOpen Targets
0.26Weak
non-small cell lung carcinomaOpen Targets
0.11Weak
lymphomaOpen Targets
0.11Weak
Waldenstrom macroglobulinemiaOpen Targets
0.11Weak
non-Hodgkins lymphomaOpen Targets
0.11Weak
leukemiaOpen Targets
0.10Weak
cancerOpen Targets
0.10Suggestive
acute myeloid leukemiaOpen Targets
0.10Suggestive
AL amyloidosisOpen Targets
0.10Suggestive
chronic graft versus host diseaseOpen Targets
0.09Suggestive
gastric cancerOpen Targets
0.09Suggestive
colorectal carcinomaOpen Targets
0.08Suggestive
Pathogenic Variants
No pathogenic variants reported on ClinVar for this gene.
View on ClinVar ↗
Drug Targets6
BORTEZOMIB D-MANNITOLApproved
26S proteasome inhibitor
Mantle cell lymphoma
CARFILZOMIBApproved
26S proteasome inhibitor
multiple myeloma
IXAZOMIBApproved
26S proteasome inhibitor
multiple myeloma
IXAZOMIB CITRATEApproved
26S proteasome inhibitor
multiple myeloma
MARIZOMIBPhase III
20S proteasome inhibitor
brain glioblastoma
OPROZOMIBPhase II
26S proteasome inhibitor
Hodgkins lymphoma
Related Genes
PSMD8Protein interaction100%PSMC6Protein interaction100%POMPProtein interaction100%PSMC1Protein interaction100%PSMD14Protein interaction100%PSMD1Protein interaction100%
Tissue Expression6 tissues
Lung
100%
Liver
82%
Brain
75%
Heart
71%
Bone Marrow
60%
Ovary
53%
Gene Interaction Network
Click a node to explore
PSMA7PSMD8PSMC6POMPPSMC1PSMD14PSMD1
PROTEIN STRUCTURE
Preparing viewer…
PDB5LE5 · 1.80 Å · X-ray
View on RCSB ↗
Constraintⓘ
LOEUFⓘ
0.37Moderately Constrained
pLIⓘ
1.00Intolerant
Observed/Expected LoF0.17 [0.09–0.37]
RankingsWhere PSMA7 stands among ~20K protein-coding genes
  • #1,092of 20,598
    Most Researched312 · top 10%
  • #377of 1,025
    FDA-Approved Drug Targets4
  • #1,678of 17,882
    Most Constrained (LOEUF)0.37 · top 10%
Genes detectedPSMA7
Sources retrieved25 papers
Response time—
📄 Sources
25▼
1
Single dose creatine improves cognitive performance and induces changes in cerebral high energy phosphates during sleep deprivation.
PMID: 38418482
Sci Rep · 2024
1.00
2
Extracellular vesicles-mediated interaction within intestinal microenvironment in inflammatory bowel disease.
PMID: 35499059
J Adv Res · 2022
0.90
3
Detection of endometrial cancer in cervico-vaginal fluid and blood plasma: leveraging proteomics and machine learning for biomarker discovery.
PMID: 38513301
EBioMedicine · 2024
0.80
4
Melittin inhibits NSCLC metastasis by targeting USP10 and promoting RNF20-mediated ubiquitination and degradation of PSMA7.
PMID: 41254650
J Transl Med · 2025
0.70
5
Negative regulation of MAVS-mediated innate immune response by PSMA7.
PMID: 19734229
J Immunol · 2009
0.64